2025-11-01
IMMU-81. Glioblastoma and other intracranial pathologies elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses
2025-11-01 • Lucas P. Wachsmuth, Bhairavy Puviindran, Selena Lorrey, Karen L. Leach, Kirit Singh, Alexandra Miggelbrink, Shannon L. Wallace, Eliese Moelker, Rac...
Abstract Immunotherapies remain largely ineffective against intracranial malignancies such as glioblastoma (GBM), in part due to profound systemic and local immune dysfunction. Hallmarks of systemic immune dysfunction include bone marrow T cell sequestration, T cell dysfunction, lymphoid organ atrophy, and lymphopenia. We report that intracranial tumors, unlike their extracranial counterparts, induce chronic sympathetic hyperactivity and significantly elevate circulating catecholamine levels in both mice and human…